Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system

View More View Less
  • 1 Department of Neurosurgery and Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, Minokamo, Gifu;
  • 2 Departments of Clinical Brain Sciences and
  • 4 Neurosurgery, Gifu University Graduate School of Medicine, Gifu; and
  • 3 Department of Neurosurgery, Tokyo Women’s Medical University, Tokyo, Japan
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Positron emission tomography (PET) is important in the noninvasive diagnostic imaging of gliomas. There are many PET studies on glioma diagnosis based on the 2007 WHO classification; however, there are no studies on glioma diagnosis using the new classification (the 2016 WHO classification). Here, the authors investigated the relationship between uptake of 11C-methionine (MET), 11C-choline (CHO), and 18F-fluorodeoxyglucose (FDG) on PET imaging and isocitrate dehydrogenase (IDH) status (wild-type [IDH-wt] or mutant [IDH-mut]) in astrocytic and oligodendroglial tumors according to the 2016 WHO classification.

METHODS

In total, 105 patients with newly diagnosed cerebral gliomas (6 diffuse astrocytomas [DAs] with IDH-wt, 6 DAs with IDH-mut, 7 anaplastic astrocytomas [AAs] with IDH-wt, 24 AAs with IDH-mut, 26 glioblastomas [GBMs] with IDH-wt, 5 GBMs with IDH-mut, 19 oligodendrogliomas [ODs], and 12 anaplastic oligodendrogliomas [AOs]) were included. All OD and AO patients had both IDH-mut and 1p/19q codeletion. The maximum standardized uptake value (SUV) of the tumor/mean SUV of normal cortex (T/N) ratios for MET, CHO, and FDG were calculated, and the mean T/N ratios of DA, AA, and GBM with IDH-wt and IDH-mut were compared. The diagnostic accuracy for distinguishing gliomas with IDH-wt from those with IDH-mut was assessed using receiver operating characteristic (ROC) curve analysis of the mean T/N ratios for the 3 PET tracers.

RESULTS

There were significant differences in the mean T/N ratios for all 3 PET tracers between the IDH-wt and IDH-mut groups of all histological classifications (p < 0.001). Among the 27 gliomas with mean T/N ratios higher than the cutoff values for all 3 PET tracers, 23 (85.2%) were classified into the IDH-wt group using ROC analysis. In DA, there were no significant differences in the T/N ratios for MET, CHO, and FDG between the IDH-wt and IDH-mut groups. In AA, the mean T/N ratios of all 3 PET tracers in the IDH-wt group were significantly higher than those in the IDH-mut group (p < 0.01). In GBM, the mean T/N ratio in the IDH-wt group was significantly higher than that in the IDH-mut group for both MET (p = 0.034) and CHO (p = 0.01). However, there was no significant difference in the ratio for FDG.

CONCLUSIONS

PET imaging using MET, CHO, and FDG was suggested to be informative for preoperatively differentiating gliomas according to the 2016 WHO classification, particularly for differentiating IDH-wt and IDH-mut tumors.

ABBREVIATIONS AA = anaplastic astrocytoma; AO = anaplastic oligodendroglioma; AUC = area under the curve; CHO = 11C-choline; DA = diffuse astrocytoma; DOR = diagnostic odds ratio; FDG = 18F-fluorodeoxyglucose; GBM = glioblastoma; IDH = isocitrate dehydrogenase; IDH-mut = mutant IDH; IDH-wt = wild-type IDH; MET = 11C-methionine; OD = oligodendroglioma; PET = positron emission tomography; R-2HG = R-2-hydroxyglutarate; ROC = receiver operating characteristic; ROI = region of interest; SUV = standardized uptake value; T/N = tumor maximal SUV/normal brain cortex mean SUV.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Hiroaki Takei: Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, Gifu, Japan. gfwgc34@gmail.com.

INCLUDE WHEN CITING Published online August 16, 2019; DOI: 10.3171/2019.5.JNS19780.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

  • 1

    Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, : IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:8191, 2014

    • Search Google Scholar
    • Export Citation
  • 2

    Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, : cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805810, 2018

    • Search Google Scholar
    • Export Citation
  • 3

    Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, : Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245254, 2010

    • Search Google Scholar
    • Export Citation
  • 4

    Cicuendez M, Lorenzo-Bosquet C, Cuberas-Borrós G, Martinez-Ricarte F, Cordero E, Martinez-Saez E, : Role of [11C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Neurosurg 139:328333, 2015

    • Search Google Scholar
    • Export Citation
  • 5

    Cohen AL, Holmen SL, Colman H: IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13:345, 2013

  • 6

    Dankbaar JW, Snijders TJ, Robe PA, Seute T, Eppinga W, Hendrikse J, : The use of 18F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. J Neurooncol 125:167175, 2015

    • Search Google Scholar
    • Export Citation
  • 7

    Delev D, Heiland DH, Franco P, Reinacher P, Mader I, Staszewski O, : Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol 141:223233, 2019

    • Search Google Scholar
    • Export Citation
  • 8

    Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, : Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:24992508, 2015

    • Search Google Scholar
    • Export Citation
  • 9

    Giovannini E, Lazzeri P, Milano A, Gaeta MC, Ciarmiello A: Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des 21:121127, 2015

    • Search Google Scholar
    • Export Citation
  • 10

    Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI, : 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:13161322, 1998

    • Search Google Scholar
    • Export Citation
  • 11

    Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, : IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:15601566, 2010

    • Search Google Scholar
    • Export Citation
  • 12

    Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, : Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29:11761182, 2008

    • Search Google Scholar
    • Export Citation
  • 13

    Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, : Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 29:18671871, 2008

    • Search Google Scholar
    • Export Citation
  • 14

    Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, : 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32:5259, 2005

    • Search Google Scholar
    • Export Citation
  • 15

    Komori T: The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir (Tokyo) 57:301311, 2017

    • Search Google Scholar
    • Export Citation
  • 16

    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer, 2016

    • Search Google Scholar
    • Export Citation
  • 17

    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, : The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803820, 2016

    • Search Google Scholar
    • Export Citation
  • 18

    Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, : Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS One 10:e0132515, 2015

    • Search Google Scholar
    • Export Citation
  • 19

    Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, : Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and l-methyl-11C-methionine. AJNR Am J Neuroradiol 17:345353, 1996

    • Search Google Scholar
    • Export Citation
  • 20

    Okamoto S, Shiga T, Hattori N, Kubo N, Takei T, Katoh N, : Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med 25:213220, 2011

    • Search Google Scholar
    • Export Citation
  • 21

    Okita Y, Kinoshita M, Goto T, Kagawa N, Kishima H, Shimosegawa E, : 11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage 49:29772982, 2010

    • Search Google Scholar
    • Export Citation
  • 22

    Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, : An integrated genomic analysis of human glioblastoma multiforme. Science 321:18071812, 2008

    • Search Google Scholar
    • Export Citation
  • 23

    Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, : Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 92:15411549, 2001

    • Search Google Scholar
    • Export Citation
  • 24

    Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T, : Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clin Nucl Med 36:639642, 2011

    • Search Google Scholar
    • Export Citation
  • 25

    Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, : Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551559, 2014

    • Search Google Scholar
    • Export Citation
  • 26

    Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A: F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study. Neuroradiology 53:10171024, 2011

    • Search Google Scholar
    • Export Citation
  • 27

    Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, : Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 22:210214, 1999

    • Search Google Scholar
    • Export Citation
  • 28

    Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC: 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 53:17091715, 2012

    • Search Google Scholar
    • Export Citation
  • 29

    Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, : R-2HG Exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. Cell 172:90105.e23, 2018

    • Search Google Scholar
    • Export Citation
  • 30

    Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, : Diagnostic and prognostic value of 11C-methionine PET for nonenhancing gliomas. AJNR Am J Neuroradiol 37:4450, 2016

    • Search Google Scholar
    • Export Citation
  • 31

    Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, : Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo) 54:280289, 2014

    • Search Google Scholar
    • Export Citation
  • 32

    Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, : Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694699, 2008

    • Search Google Scholar
    • Export Citation
  • 33

    Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, : Methyl-l-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 50:19621968, 2009

    • Search Google Scholar
    • Export Citation
  • 34

    Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, : Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679693, 2015

    • Search Google Scholar
    • Export Citation
  • 35

    Wiestler B, Capper D, Sill M, Jones DTW, Hovestadt V, Sturm D, : Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128:561571, 2014

    • Search Google Scholar
    • Export Citation
  • 36

    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765773, 2009

  • 37

    Zhao C, Zhang Y, Wang J: A meta-analysis on the diagnostic performance of 18F-FDG and 11C-methionine PET for differentiating brain tumors. AJNR Am J Neuroradiol 35:10581065, 2014

    • Search Google Scholar
    • Export Citation

Metrics